the-express.com
Jan 26, 2025, 17:30
Pan-RAS Inhibitor Shows Early, Deep Molecular Responses in PDAC
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X:
“Pan-RAS inhibitor Daraxonrasib in 2L of pancreatic cancer
ORR KRAS G12X: 36%, RAS mt: 27%
For comparison ORR with nal-IRI-FU/LV in NAPOLI-1: 7.7%.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 17:18
Apr 1, 2025, 16:18
Apr 1, 2025, 14:35